Security key
36269B105
- Security type / class
- Equity / COM
- Total 13F shares
- 13,500
- Total 13F value
- $23,355
- Share change
- -21,500
- SEC-reported price per share
- $1.73
- Number of holders
- 1
- Value change
- -$37,195
- Number of sells
- 1
Report period
Q3 2026
Institutions
1
Top holders
1
GANX full security history
Ownership snapshot
Full 13F holder table
Gain Therapeutics, Inc. SEC filings
Gain Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36269B105
Recent filing periods:
Ownership snapshot
Top reported holders of GANX - Gain Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MARSHALL WACE, LLP
Disclosed value leader
MARSHALL WACE, LLP
Comparable rows
0/15
Latest evidence
15 Jul 2026
13F
3/4/5
Highest disclosed value: $3,904,799
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
MARSHALL WACE, LLP has the largest disclosed position value at $3.9M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MARSHALL WACE, LLP's linked filing trail.
Disclosed position value
Top 5
MARSHALL WACE, LLP
$3.9M
Potomac Capital Management, Inc.
$1.92M
GSA CAPITAL PARTNERS LLP
$1.28M
Eric I. Richman
$1.17M
Cambridge Investment Research Adv...
$1.15M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP |
13F
Company
|
—
class O/S missing
|
$3,904,799
1,923,546 shares
|
— | 30 Jun 2026 |
| Potomac Capital Management, Inc. |
13F
Company
|
—
class O/S missing
|
$1,921,192
946,400 shares
|
— | 30 Jun 2026 |
| GSA CAPITAL PARTNERS LLP |
13F
Company
|
—
class O/S missing
|
$1,283,000
632,131 shares
|
— | 30 Jun 2026 |
| Eric I. Richman |
3/4/5
Director
|
—
mixed-class rows
|
$1,174,903
319,458 shares
mixed-class rows
|
— | 24 Jun 2025 |
| Cambridge Investment Research Advisors, Inc. |
13F
Company
|
—
class O/S missing
|
$1,154,000
568,645 shares
|
— | 30 Jun 2026 |
| DME Capital Management, LP |
13F
Company
|
—
class O/S missing
|
$1,149,244
566,130 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
13,500
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
50
Q3 2026 holders
1
Holder diff
-49
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend